🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📣Updated: ESMO Guidelines Slideset: Non-Oncogene-Addicted Metastatic Non-small Cell Lung Cancer v1.2 Find Clinical Practice Guideline recommendations in a condensed format, to include in your presentations. #ESMOGuidelines 🔗 ow.ly/1RLG50VjggF

📣Join us for the upcoming #ESMOGuidelines Webinar! Dive deep into EGFR-mutated #mNSCLC, resistance mechanisms, and cutting-edge second-line therapies. Expert insights, real-world cases & evidence-based strategies await! 🔗Register now: ow.ly/7k8F50Vlsrm

📣Updated: ESMO Guidelines Slideset: Oncogene-Addicted Metastatic Non-small Cell Lung Cancer v1.2 👉 Find Clinical Practice Guideline recommendations in a condensed format, to include in your presentations. #ESMOGuidelines 🔗ow.ly/sGmE50VnVwU

#ELCC25 ADCs in NSCLC Superb overview by Lizza Hendriks identifying gaps in our knowledge: - ideal pt population - biomarker selection - is it be used to spare chemo? ESMO - Eur. Oncology OncoAlert #LCSM

#ELCC25 saves the best for last!! Day 4 with two cutting-edge sessions focusing on #IO resistance and next generation #ADCs . Happy to discuss the role of ADCs in oncogene-addicted NSC among bright colleagues and friends #ESMOAmbassadors Lizza Hendriks Benjamin Besse Noemi Reguart

Very happy to share that I have been nominated for IASLC board of directors! Contributing to fostering, mentoring and teaching the new generation of colleagues combined with moving the field of thoracic oncology forward is my passion. Please vote lnkd.in/e3B24W8r

Elections for members of the IASLC board are open with many excellent candidates from all over the 🌍🌎🌏 including those amazing 4 ladies passionate for lung cancer awareness , education and research. Please vote for the people you believe in! Good luck to all!

Spoiled with a stellar bunch of RadOncs to vote for this IASLC election: - Andrea Bezjak - Sara Ramella - Ken Harada Plus legendary friends of RadOnc such as Lizza Hendriks Triparna Sen (Sen-Lab) Hidehito HORINOUCHI & Narjust Florez, MD, FASCO As they say - vote early, vote often!

Thank you so much Giannis Mountzios for the kind words! Your support truly means a lot. I am honored to be among such an incredible group of IASLC Board candidates. IASLC Board of Directors Basic Science seat- if elected, I am committed to continue working towards: ✅Advancing

Out now in Lung Cancer Journal: Multimodality treatment in synchronous oligometastatic NSCLC: Analysis of the ETOP CHESS trial: authors.elsevier.com/a/1l0RScYZOisEb Cohort 2 with Tremelimumab in addition to Durvalumab is still recruiting: etop.ibcsg.org/projects/clini… Grupo Español de Cáncer de Pulmón; SAKK

The Electronic Ballot Vote to elect the ESMO Directors and Nomination Committee Chair and members is now open! ESMO - Eur. Oncology members opportunity to vote for my wonderful lung colleagues Martin Reck Noemi Reguart Sanjay Popat ! #LCSM

Α big lung cancer family comes together every year and ASCO united by a common passion and vision and of course by our unique host Marina Garassino !! #ASCO25

☑️#ASCO25 🆙 ☑️#LCSM Oral, LocReg/SCLC 🔥DISCUSSION: The Earlier the Better? From Detection to Treatment of Localized Lung Cancer 🎙️ Lizza Hendriks OncoAlert ASCO meetings.asco.org/2025-asco-annu…

#ASCO25 Lung orals🔥 Accomplished discussion by Lizza Hendriks of CM816, NeoADAURA & Deluge LC screening/IPN study. Key next steps: - 816: next gen ways to predict pCR - Neoadaura: eval endpte - DELUGE: reeval smoking hx in LCS risk scores Bravo 👏🏻 ASCO OncoAlert #LCSM

EORTC Lung Group present at ASCO 2025! Excellent oral abstract discussions of Chair Jordi Remon and Secretary Lizza Hendriks EORTC

#ASCO25: Final results from #CheckMate816 confirm OS benefit—nivolumab + chemo cuts risk of death by 28% in resectable #NSCLC. 5-year OS: 65.4% vs 55.0%. A paradigm shift is now standard. bit.ly/4jyjZSl Lizza Hendriks Patrick Forde NEJM

📣Updated ESMO #ClinicalPracticeGuideline recommendations in the non-oncogene-addicted metastatic #NSCLC: new 1L Tx options approved. 🔗 ow.ly/kzQF50Wa0lf #LungCancer #mNSCLC #ESMOGuidelines

#ASCO25: Final results from #CheckMate816 confirm OS benefit—nivolumab + chemo cuts risk of death by 28% in resectable #NSCLC. 5-year OS: 65.4% vs 55.0%. A paradigm shift is now standard. bit.ly/4jyjZSl Lizza Hendriks Patrick Forde NEJM

📣Updated ESMO #ClinicalPracticeGuideline recommendations in oncogene-addicted metastatic #NSCLC: more #TargetedTherapy agents now available in 1L or at resistance. #LungCancer #mNSCLC #ESMOGuidelines 🔗 ow.ly/v7nE50Wbqsf

In NSCLC & AGA we usually use the ⬆️ dose of targeted therapies despite no always correlation btw dose and efficacy or intracranial activity.In this review, we discuss these topics. Is time to redefine doses of TT as now applied across stages? doi.org/10.1016/j.ctrv…